Why your medicine might not be doing exactly what the label promises
In short: Bioavailability measures how much of a substance actually reaches your systemic circulation to do its work. While intravenous delivery guarantees 100% absorption, oral medications face a gauntlet of biological barriers. Understanding this fraction, denoted as F, is essential for ensuring that your treatment remains both safe and effective.
At its core, bioavailability is the percentage of an administered dose that enters the bloodstream unchanged. Intravenous administration serves as the gold standard with 100% bioavailability, but most other routes—such as oral, nasal, or transdermal—fall short. This reduction occurs because substances must survive intestinal absorption and first-pass metabolism in the liver before reaching circulation. Scientists quantify this by calculating the area under the plasma drug concentration curve (AUC) over time, comparing the extravascular dose to an intravenous reference.
Determining absolute bioavailability is complex and costly, often requiring an intravenous study to establish a baseline. To bypass the need for full-scale intravenous testing, researchers sometimes use isotopically labelled drugs. By administering a tiny, safe dose of a labelled substance alongside a standard oral dose, they can distinguish the two in the blood using mass spectrometry. This allows for precise pharmacokinetic data without the risks associated with larger intravenous doses. Regulatory bodies like the FDA typically only demand this data when bioavailability is notably low or variable.
The journey from ingestion to systemic circulation is fraught with variables. Factors ranging from physical properties like solubility to external influences such as grapefruit juice or concurrent medications can drastically alter absorption. Even individual physiology—age, gender, and metabolic health—creates significant inter-individual variation. Because of this, clinical trials must account for these fluctuations to ensure predictable dosing. For nutritional supplements, the challenge is even greater; without the rigorous standards of the pharmaceutical industry, bioavailability remains a fluid concept dependent on the subject's specific nutritional and physiological state.
When comparing different drug formulations, scientists use relative bioavailability to assess bioequivalence. For generic drugs to gain FDA approval, they must demonstrate that their performance falls within 80% to 125% of the brand-name product's response. While drugs like theophylline can occasionally exceed 100% bioavailability due to unique metabolic pathways, most substances require careful calibration to ensure that the bottom of the deviation range still provides the intended therapeutic effect.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Bioavailability
To cite this card, link to https://intellectplus.co.uk/app/nature-bioavailability.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Earth science · More in Nature · Latest · A–Z · All topics
